stockrowLyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.
- Revenue
- −80.0%
- EPS
- +12.7%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow LYEL
Alert me
Lyell Immunopharma, Inc. (LYEL) EV/Sales
As of 6 November 2026, Lyell Immunopharma, Inc. (LYEL) trades at a EV/Sales of 12,336×. Over the past ten years it has ranged from −4,572× (December 2024) to 13,329× (November 2026); the current reading is higher than 100% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7,747× | — |
| FY2024 | −3,331× | — |
| FY2023 | −128× | — |
| FY2022 | 2.2× | (94.53%) |
| FY2021 | 41.1× | — |
| FY2020 | −39.7× | — |
| FY2019 | −39.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 4,141× | (9.94%) |
| Jun 2026 | 4,599× | (22.86%) |
| Mar 2026 | 5,962× | (23.05%) |
| Dec 2025 | 7,747× | — |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | −68.8× |
| ZURA Zura Bio Limited compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | 2.0× |
| CCCC C4 Therapeutics, Inc. compare | 7.4× |
| ALT Altimmune, Inc. compare | 1,970× |
| LYEL Lyell Immunopharma, Inc. | 12,336× |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)